Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Novacyt  /  Novacyt de volgende biotech raket!

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Novacyt PSE:ALNOV.FR, FR0010397232

  • 0,831 30 apr 2024 17:35
  • +0,003 (+0,36%) Dagrange 0,813 - 0,860
  • 370.440 Gem. (3M) 186,9K

Novacyt de volgende biotech raket!

70.378 Posts
Pagina: «« 1 ... 30 31 32 33 34 ... 3519 »» | Laatste | Omlaag ↓
  1. Speculatie 28 januari 2020 08:57
    Novacyt begon 2020 met een aanzienlijk hoger orderboek dan vorig jaar op hetzelfde moment. Lab21 Products heeft aan het einde van het jaar orders ter waarde van 1,6 miljoen euro. Op deze bestellingen kon 1,3 miljoen euro niet worden geleverd vanwege werkkapitaal- en supply chain-problemen en zou in de eerste helft van 2020 moeten worden voldaan.

    Sinds de aankondiging van een nieuwe lening en de annulering van de converteerbare obligatiefaciliteit in november 2019, is Novacyt begonnen met het investeren van fondsen om de supply chain nieuw leven in te blazen. Het management verwacht dat het grootste deel van de eerste helft van 2020 nodig zal zijn om de productieproductie en de normale voorraadniveaus volledig te herstellen.

    Op 31 december 2019 had de groep geldmiddelen en kasequivalenten van 1,8 miljoen euro (2018: 1,1 miljoen euro).

    In 2020 zal het management zich blijven richten op het verhogen van de brutomarges en de winstgevendheid van EBITDA, terwijl het werkkapitaal zorgvuldig wordt beheerd om de voorraadniveaus te herstellen en duurzame omzetgroei te garanderen. Verwachte kostenbesparingen zullen niet alleen de winstgevendheid verbeteren, maar ook de cashflow van het bedrijf verlengen en meer investeren in de wederopbouw van de supply chain, die tegen die tijd voltooid zou moeten zijn het midden van 2020.

    De verkoop van NOVAprep's resterende activa zou in de eerste helft van het jaar extra liquiditeit kunnen genereren, wat het werkkapitaal zou verhogen. Er zijn momenteel onderhandelingen gaande met verschillende partijen om de resterende instrumenten en ook een deel van het resterende intellectuele eigendom te verkopen na de succesvolle verkoop van bepaalde activa aan Algimed Trade Ltd in december 2019 voor 0,4 ME plus royalty's.
  2. Speculatie 28 januari 2020 08:58
    (Boursier.com) - Novacyt rapporteert een geconsolideerde omzet van ongeveer 13,1 miljoen euro voor het gehele boekjaar 2019, een daling van 5% en 6% bij constante wisselkoersen. Exclusief Clinical Lab, dat in juli 2019 werd verkocht, daalde de omzet met 2% (3% tegen constante wisselkoersen). Vanwege de lange doorlooptijden van de productie was het moeilijk om een ??aanzienlijk herstel te realiseren in de laatste weken van 2019, omdat de financiering pas in november 2019 werd voltooid. Met de achteruitgang van de handel heeft het management verwacht nu dat de EBITDA voor het hele jaar lager zal zijn dan vorig jaar.
  7. TimTim17 28 januari 2020 09:43
    FULL YEAR TRADING AND OPERATIONAL UPDATE
    Paris, France and Camberley, UK – 28 January 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited revenues for the year ended 31 December 2019 and provides an operational update. The Company will report its full year results in April 2020.

    Graham Mullis, Group CEO of Novacyt, commented:
    “I am encouraged that last year we completed the disposal of the two non-core businesses and also completed a major restructure of the balance sheet to provide much needed working capital. Despite working capital constraints, which impacted most of 2019, we demonstrated significant levels of growth in key parts of the business and continue to see increasing demand for our products. I look
    forward to growing the business from a stronger financial position in 2020.”

    2019 Trading Update
    The Company announces that year end revenues from continuing operations will be approximately €13.1m, a reduction of 5% (6% CER) on a consolidated basis compared to 2018. Excluding the Clinical Lab, which was sold in July 2019, revenue reduced by 2% (3% CER). As previously announced, trading was impacted from the second quarter of 2019 onwards due to working capital constraints. Long
    manufacturing lead times meant that it was challenging to achieve any significant recovery in the last few weeks of 2019 given that the financing was only completed in November 2019. With the lower trading, management now expect the full year EBITDA to be lower than the prior year. The Company has started 2020 with an order book significantly higher than at the same time last year. Lab21 Products had confirmed orders of €1.6m at the end of the year. Of these orders, €1.3m could not be delivered due to working capital and supply chain issues and are expected to be fulfilled during the first half of 2020.
    Since the announcement of a new term loan and cancellation of the convertible bond facility in November 2019, Novacyt has started to invest funds in the recovery of its supply chain. The Company expects that it will take most of the first half of 2020 to fully restore manufacturing output and stock to normal levels.
    Core reagent sales across the Group grew by 3% year-on-year, with Primerdesign delivering 8% higher reagent revenues. Primerdesign also achieved international revenue growth of 12% despite restricted q16 instrument sales due to lack of stock. This strong international performance was largely offset by weaker sales in the smaller UK direct market (down 13%) following a restructuring of the
    commercial team in the second quarter of 2019. Microgen Bioproducts sales, part of the Lab21 Products business were also strong despite the continued stock shortages, as demonstrated by the UK and Ireland direct sales increasing by 13% and Middle East sales increasing by 8% on the prior year.

    The discontinued NOVAprep® operation achieved sales of €1.3m, which are excluded from Group consolidated revenue and do not impact the growth metrics stated above. These sales were generated before the sale of the business in December 2019 and represent 37% growth compared to the prior year which helped the division deliver positive cash flow for the Group in 2020, with a significant net cash contribution of €0.7m in the second half of the year.
    At 31 December 2019, the Group held cash and cash equivalents of €1.8m (2018: €1.1m).

    Operational update
    Development of new coronavirus test Primerdesign is pleased to report that it is in the final stages of developing a new molecular novel coronavirus (2019-nCoV) test as a direct response to the recent outbreak of the potentially deadly respiratory virus in China. The Company will make the test available as a research use only (RUO) test for use on Primerdesign’s proprietary genesig® Q16 and Q32 instruments, as well as a number of other real-time PCR instruments commonly used in testing laboratories. A number of Novacyt’s customers have already enquired about the availability of this test and orders have already been received.
    This virus is of major concern as it is from the same family of viruses as severe acute respiratory syndrome (SARS), which emerged in China in 2002 and killed nearly 800 people worldwide. Authorities have recently confirmed that the virus can be passed from person to person via airborne transmission
    sparking concerns over the level of contagion. The World Health Organisation (WHO) reported that, as of 22 January, countries including the US, Singapore, Australia, Japan, Thailand and Korea are reporting the presence of this infection. The virus is not currently considered a global health
    emergency as designated by the WHO but this may change as more data becomes available. The Primerdesign test is therefore well positioned to quickly assist affected countries.

    Manufacturing site consolidation:
    Following the successful sale of two non-core businesses in 2019, and as part of the strategy to increase profitability, the Company will close its manufacturing facility in Bridport and transfer production to its Camberley site by the end of the first quarter of 2020. In addition to the overhead savings that the consolidation of operations is forecast to deliver,
    management is confident that this relocation will also deliver additional operating profit to the Group. Following the site consolidation, Novacyt will operate from just two sites in the UK based in Southampton and Camberley.

    Outlook for 2020
    In 2020, management will continue to focus on increasing gross margins and EBITDA profitability while carefully managing working capital to restore stock levels and deliver sustainable revenue growth. The planned overhead savings will not only improve profitability but extend the Company’s cash runway and enable further investment in rebuilding the supply chain, which is expected to be completed by the middle of 2020.
    Further cash could be generated in the first half of the year from the sale of the residual NOVAprep® assets, which would provide further working capital. Negotiations are currently underway with various parties to sell the remaining instruments and also some of the residual IP following the successful sale
    of certain assets to Algimed Trade Ltd in December 2019 for €0.4m plus royalties.

    Following the successful disposals of the Clinical Lab and NOVAprep® assets and the completion of the financing in 2019, management is focused on driving core business sales growth and profitability in 2020. The year starts with a strong sales order book, new business (VGS Group) and a strong pipeline of new customers for the recently launched PathFlow™ product range in infectious diseases.

    This announcement contains inside information for the purposes of Article 7 of Regulation (EU)
    596/2014
  10. TimTim17 28 januari 2020 09:51
    Wellicht niet de piek die we nu gehoopt hadden maar wel een solide basis om verder op te kunnen groeien in 2020. Ik zie dit als uitbodemen rond de 20 cent om vervolgens gestaagd verder te groeien de komende periode.

    Er zijn al een aantal punten benoemd die verdere groei in de koers zullen rechtvaardigen.
70.378 Posts
Pagina: «« 1 ... 30 31 32 33 34 ... 3519 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!